AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8225637
Drug: Amoxycillin (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin (125 mg for <25 kg or 250 mg for >25 kg, three times daily for 5 days)
Trial: 12618501
Drug: Vinorelbine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine (30 mg/m²)
Trial: 12618501
Drug: Gemcitabine (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (1200 mg/m²)
Trial: 12618501
Drug: Vinorelbine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine (25 mg/m²) plus Gemcitabine (1000 mg/m²)
Trial: 12618501
Drug: Quality of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quality of life across all treatment arms
Trial: 8145392
Drug: Males spending
RxNorm normalized name: Malus domestica leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Males spending 7 hours or more outside daily
Trial: 3021500
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (4 mg q.i.d.)
Trial: 14631124
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with azathioprine (AZA) and interferon beta(1a)
Trial: 9407252
Drug: Increased carbohydrate
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased carbohydrate intake (CHO) of 10 g.kg‐1 bm during the 22‐hr recovery
Trial: 8498900
Drug: Subcutaneous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous recombinant human erythropoietin (rh‐EPO) therapy
Trial: 8498900
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no rh‐EPO therapy in the first year)
Trial: 3079056
Drug: Antilymphoblast globulin
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antilymphoblast globulin (ALG) therapy
Trial: 28752418
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplementation (120 mg docosahexaenoic acid and 180 mg eicosapentaenoic acid) daily
Trial: 24942756
Drug: Irradiated, granulocyte‐macrophage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irradiated, granulocyte‐macrophage colony‐stimulating factor (GM‐CSF)‐secreting, allogeneic PDAC vaccine (GVAX)
Trial: 24942756
Drug: GVAX in
RxNorm normalized name: GVAX
DrugBank: GVAX (DB17276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GVAX in combination with low‐dose cyclophosphamide
Trial: 22526159
Drug: Intravenous treosulfan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous treosulfan (7,000 mg/m2 on day 1 of a 28-day cycle)
Trial: 22526159
Drug: Oral treosulfan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral treosulfan (600 mg/m2 on days 1-28 of a 56-day cycle)
Trial: 18374336
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of pioglitazone and simvastatin
Trial: 15991880
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate 800 mg following a standard high‐fat content meal
Trial: 15991880
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate 800 mg following 10 hours of fasting
Trial: 12495202
Drug: Sulfated polysaccharides
RxNorm normalized name: sulfated mucopolysaccharides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfated polysaccharides from red microalgae (topical application)
Trial: 10384681
Drug: SF-36 administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SF-36 administered via in-person or telephone interviews
Trial: 10384681
Drug: Self-administered SF-36
RxNorm normalized name: SF-RI 1
DrugBank: Calfactant (DB06415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered SF-36
Trial: 8679062
Drug: Antidementia drug
RxNorm normalized name: metoclopramide
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antidementia drug tacrine
Trial: 7070885
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg albuterol syrup (2 mg/5 ml) four times a day
Trial: 7070885
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg albuterol syrup
Trial: 7070885
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg albuterol tablets
Trial: 3511776
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg albuterol
Trial: 30831103
Drug: Buccal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Buccal misoprostol 800 mcg every 3 hours for three doses
Trial: 30831103
Drug: Sublingual misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual misoprostol 800 mcg every 3 hours for three doses
Trial: 30831103
Drug: Buccal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Buccal misoprostol with additional misoprostol at follow-up
Trial: 30831103
Drug: Sublingual misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual misoprostol with additional misoprostol at follow-up
Trial: 17237451
Drug: Formats with
RxNorm normalized name: formate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formats with a number (e.g., pie charts, vertical bars, horizontal bars, digits, systematic ovals, random ovals)
Trial: 17237451
Drug: Formats with
RxNorm normalized name: formate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formats with only a scale (e.g., pie charts, random ovals)
Trial: 15281471
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate DPI, 400 microg every evening (1 puff daily)
Trial: 15281471
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate MDI, two 125-microg puffs twice daily
Trial: 12045412
Drug: Various medications
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various medications for treatment of status asthmaticus; specific drugs, doses, and duration not available.
Trial: 12045412
Drug: Elimination of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elimination of cost-adding treatments without improved quality of care; specific interventions not available.
Trial: 2172395
Drug: Intranasal beclomethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal beclomethasone (168 micrograms twice a day) and oral prednisone (30 mg twice daily)
Trial: 9467537
Drug: Midodrine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midodrine (10 mg)
Trial: 24471250
Drug: Prasugrel (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (loading dose of 60 mg followed by maintenance dose of 10 mg once daily)
Trial: 24471250
Drug: Clopidogrel (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (loading dose of 300 mg followed by maintenance dose of 75 mg once daily)
Trial: 21212103
Drug: High-dose octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose octreotide LAR (60 mg/28 days)
Trial: 21212103
Drug: High-frequency octreotide
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-frequency octreotide LAR (30 mg/21 days)
Trial: 21212103
Drug: High-dose octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose octreotide LAR
Trial: 17302367
Drug: LB80380 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LB80380 30 mg once per day
Trial: 17302367
Drug: LB80380 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LB80380 60 mg once per day
Trial: 17302367
Drug: LB80380 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LB80380 120 mg once per day
Trial: 17302367
Drug: LB80380 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LB80380 240 mg once per day
Trial: 8811473
Drug: 1% aqueous
RxNorm normalized name: Zotane-HC 0.1%-1%-1% Aqueous Otic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% aqueous solution of delmopinol hydrochloride applied 2 times a day for 7 days
Trial: 8811473
Drug: 1% aqueous
RxNorm normalized name: Zotane-HC 0.1%-1%-1% Aqueous Otic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% aqueous solution of delmopinol hydrochloride applied on previously placebo-treated surfaces
Trial: 27235114
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy intervention group (MTG)
Trial: 24877181
Drug: Azacitidine 25-100
RxNorm normalized name: azacitidine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azacitidine 25-100 mg/m2 SC doses in patients with normal renal function (n=21)
Trial: 24877181
Drug: Azacitidine 75
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine 75 mg/m2 SC doses for 5 consecutive days in patients with severe renal impairment (n=6)
Trial: 24877181
Drug: Azacitidine 75
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine 75 mg/m2 SC doses (multiple doses)
Trial: 24257722
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g whey protein
Trial: 24257722
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g whey protein
Trial: 22338070
Drug: 35 g
RxNorm normalized name: SODIUM CHLORIDE 0.135 g in 15 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 g whey protein
Trial: 19958428
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of three full‐face IPL treatments and six full‐face topical antioxidant applications (Group C)
Trial: 19958428
Drug: Three full‐face
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three full‐face IPL treatments (Group A)